Clinical data supporting approval demonstrated non-inferior immune responses for all serotypes shared with PCV13 following a four-dose series and superior immune responses for important disease-causing shared serotype 3 and unique serotypes 22F and 33F compared to PCV13
With this expanded indication, VAXNEUVANCE is the first pneumococcal conjugate vaccine approved in almost a decade to help protect pediatric populations against invasive pneumococcal disease
https://finance.yahoo.com/news/u-fda-approves-merck-vaxneuvance-104500312.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.